What is the efficacy of vaccination against herpes zoster (shingles)?

Updated: Jan 25, 2019
  • Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print
Answer

A live attenuated VZV vaccine introduced in 2005 (Zostavax) has demonstrated a reduction in the incidence rate of herpes zoster. It is approved for use in patients aged 50 years and older and has been judged to be cost-effective. [8] The new zoster vaccine recombinant (adjuvanted) (Shingrix) has been approved by the US Food and Drug Administration (FDA). It has been judged more effective than the current vaccine and has been deemed safe and effective for adults aged 50 years and older, based on two randomized, placebo-controlled, observer-blind clinical trials. [9, 10]

See Treatment and Medication for more detail.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!